Research
Hormonal
Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.
Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.
StrongSupportsHIGH confidence
semaglutide 2.4 mg once weekly in patients with MASH and fibrosis F2/F3, demonstrated significant improvement in both MASH resolution and liver fibrosis regression of >1 stage, leading to FDA conditional approval for the treatment of patients with fibrotic MASH.
Why this rating
Based on Phase III RCTs (ESSENCE) and pooled data from STEP trials.
Source
Management of obesity in advanced chronic liver disease
Cyrielle Caussy et al. · JHEP Reports · 2026
DOI 10.1016/j.jhepr.2026.101749
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.Good
- Bariatric surgery is an effective and durable weight-loss intervention that reduces major adverse liver outcomes (MALO) and cardiovascular events in patients with MASH, though data in advanced cirrhosis is limited.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →